Category Archives: Human Longevity

DUBLIN--(BUSINESS WIRE)--The "Global Longevity and Anti-Senescence Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on the study of genomics, microbiome, bioinformatics, and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy, and Others. Senolytic drug therapy held the largest market revenue share in 2017. The fastest growth of the gene therapy segment is due to the Large investments in genomics.

Report Scope

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023.

The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Global Longevity and Anti-senescence Market by Therapy

Chapter 5 Global Longevity and Anti-senescence Market by Application

Chapter 6 Global Longevity and Anti-senescence Market by Region

Chapter 7 Industry Structure in Longevity and Anti-senescence Market

Chapter 8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/zy7jt

More:

Global Longevity & Anti-Senescence Therapy Market Review 2017-2018 and Forecast to 2023 - ResearchAndMarkets.com - Business Wire

PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning organs within a patient's own body. This financing will enable LyGenesis's lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.

"We have advanced our liver regeneration program through preclinical trials and this financing will help us to rapidly transition into a clinical-stage biotechnology company," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis. "Our ability to use the lymph node as a bioreactor for organogenesis is also generating interest from partner companies looking for an enabling technology so that their genetically modified cell therapies are able to engraft, proliferate, vascularize, and produce a therapeutic effect in patients."

"We are thrilled to continue our financial support of LyGenesis as they transition into clinical development," said Greg Bailey, MD, Co-Founder and CEO of Juvenescence, and a member of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "The ability to regenerate functioning ectopic organs was science fiction just a few short years ago. The progress of LyGenesis's technology is emblematic of the rapid advances we are witnessing as biotechnology transitions from bench research, to preclinical models, and now into the clinic."

About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

About Juvenescence, Ltd.Juvenescence Limited is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvenescence.ltd.

About Longevity Vision FundLongevity Vision Fundis a $100M life extension-focused investment fund dedicated to making longevity affordable and accessible to all. Founded by Sergey Young, the fund accelerates breakthroughs in longevity by investing in start-ups and companies that develop technologies, products, and services that extend human lifespans and overcome the negative effects of aging. The Fund provides funding to biotech and life extension-focused companies developing early diagnostics, AI in healthcare, and therapies addressing age-related diseases. To learn more, please visit lvf.vc.

Media Contact:Michael Hufford, PhD+1.858.603.2514226496@email4pr.com

SOURCE LyGenesis, Inc.

http://www.lygenesis.com

See more here:

LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology - PRNewswire

Although it is one natural ability of human beings to think and it is what sets us apart from animals, but when you get overboard with thinking, it can get detrimental. A new study suggests that overthinking can shorten your lifespan.

The study conducted by the researchers at Harvard Medical School has found that excessive brain activity could decrease ones lifespan. It involved individuals aged 60-70 years whose brains were compared to those who lived until they were 100 or more.

Their findings suggested that people who died at younger ages had significantly lower levels of the protein REST (RE-1 silencing Transcription)- one that silences your brain activity. Precisely, the study showed that overthinking causes excessive brain activity which in turn leads to depletion in ones REST protein levels and shortened lifespan. And that suppressing such overactivity extends life. Several other studies have also proved that REST protein offers protection against Alzheimers disease.

This is the first study to prove that the activity of the nervous system affects the longevity of human beings. Though several studies have previously reported the phenomenon among animals, the role of neural activity in human aging has remained murky until now.

The lead author Bruce Yankner, professor of genetics at HMS and co-director of thePaul F. Glenn Center for the Biology of Agingsaid,An intriguing aspect of our findings is that something as transient as the activity state of neural circuits could have such far-ranging consequences for physiology and life span. He added that they now have several individuals enrolled in such studies to partition the aging population into genetic subgroups. He also opines that this information is invaluable and makes it evident as to why it's so important to support the future of human genetics.

The study has paved the way for designing new therapies for health conditions that are associated with neural overactivity including Alzheimers disease and bipolar diseases. The study results also create the possibility that meditation or medicines that can target REST protein could extend the human life span by modulating neural activity.

"The possibility that being able to activate REST would reduce excitatory neural activity and slow aging in humans is extremely exciting," said the study co-authorMonica Colaicovo, professor of genetics at Harvard Medical School.

Overthinking Photo: Jambulboy, Pixabay

Originally posted here:

Overthinking Can Shorten Your Life, Says New Study - International Business Times

Artificial Intelligence in Health Care, Healthy Longevity, and Human Genome Editing Among Topics at Meeting of Nations Top Health Leaders and Scholars Oct. 21

The National Academy of Medicines (NAM) 49th Annual Meetingwill include a scientific symposium Oct. 21 featuring a keynote address by Keith A. Wailoo, professor of history and public affairs at Princeton University, and panel discussions on data sharing and patient privacy; artificial intelligence in health care delivery; and the ethics and governance of human genome editing.

Following the symposium, NAM President Victor J. Dzau will moderate a Presidents Forum on the societal implications of emerging science and technology in health and medicine and the need for a future multisectoral, collective governance framework to guide the development and adoption of new technologies. The forum begins at 4:30 p.m. EDT and willfeatureremarks byRobert Cook-Deegan(Arizona State University),Scott Gottlieb(American Enterprise Institute),Vivian S. Lee(Verily),Alondra Nelson(Institute for AdvancedStudy), andElias A. Zerhouni(Johns Hopkins University).

Beginning at 6 p.m. EDT, NAM will celebrate the launch of its Healthy Longevity Global Competition, a multiyear, multimillion-dollar international competition hosted jointly by the National Academy of Medicine and global collaborator organizations. The competition will seek breakthrough innovations to extend human health and function later in life and will follow a unique model built on a foundation of catalyst and proof-of-concept awards to attract bold ideas and to advance successful pilots and prototypes, followed by major inducement prizes. In addition to Dr. Dzau, speakers at the reception include:

Details:Monday, Oct. 21, 10:15 a.m. - 7 p.m. EDT, Fred Kavli AuditoriumNational Academy of Sciences building2101 Constitution Ave., N.W.Washington, D.C.Agenda|WebcastReporters who wish to attend the meeting in person should register in advance.

Contact:Dana Korsen, Media Relations ManagerOffice of News and Public Information202-334-2138; e-mail news@nas.edu

Twitter: @theNAMedicineFacebook: @NAMedicineInstagram: thenamedicineFollow the conversation using #NAMmtg

Follow this link:

Media Advisory: Artificial Intelligence in Health Care, Healthy Longevity, and Human Genome Editing Among Topics at Meeting of Nation's Top Health...

Share This Article:Startup teams at an EvoNesus incubator in downtown San Diego. Photo by Chris JenneweinBy Duane Cameron

Everyone in business and economic development agree that startups are great for citiesbut how can communities and leaders do more than just tout the benefits of startups, and actually help pave the way for entrepreneurs to bring their business ideas to life?

Support Times of San Diego's growthwith a small monthly contribution

One way of getting behind San Diego startups is through celebrating the innovation and creativity being brought to our region. This month Cox Business, Tech Coast Angels and the San Diego Venture Group are doing exactly that by sponsoring and organizing the John G. Watson Quick Pitch Competition.

The Quick Pitch Competition on Oct. 29 gives 10 local startups the opportunity to compete for grants of up to $50,000 to further develop their idea. Its one of several others like it throughout the year here in our region.

However, we can always do more to support our startup ecosystemespecially if we want to hang on to our distinction as one of the best cities in America to launch a business. Moreover, San Diego in particular has a number of very good reasons to do so:

Small businesses, including startups, are the backbone of our regional economy. Small businesses, defined as those with 100 employees or fewer, employ697,000 people, or 59 percentof San Diegos workforce. If we were to attract fewer talented entrepreneurs, opportunities for both our long-time residents and recent transplants would dry up, and our economy would suffer.

Theyve given us our reputation as a life sciences and biotechnology innovation hub. Aside from the San Francisco Bay Area and the Boston-Cambridge region, were one of the top cities for manufacturing, testing and research in the fields of biotechnology, pharmaceuticals and medical devices. Several of the top employers in this area are, of course, large companies like Illumina, but a vast majority of the more than 1,100 life and sciences biotech businesses in San Diego began life as small startups with an idea.

They encourage competition. Competition is a good thing and spurs innovation, and a competitive business ecosystem makes our city stand out as a dynamic source of tech solutions. As Ben Yoskowitz, an angel investor and founding partner at Year One Labs puts it, Any reasonably good idea has 10,000 people working on it right now.

A few local startups have made it big already. Thanks to our large pool of talent both local and transplanted (the perks of being a major center for universities) as well as a good network of accelerators that coach startups on how to prepare for a successful launch, many of our startups have emerged as major players on the national scene. Think GoFundMe, Classy, Brain Corp, and Human Longevity. Imagine how many more ideas like these are currently incubating among San Diegos startup founders.

They employ talent from other tech hubs, especially recent graduates. The job market may have improved greatly since the 2008-2009 recession, and unemployment may be low, but its still challenging to get your foot in the door as a recent college graduate. In cities like San Diego, though, where theres a strong pool of startups, these young professionals can easily find employment that develops them professionally into the future talent that our city will need to continue to grow.

San Diego has steadily climbed higher on lists of top U.S. cities for startups over the past few years, but that didnt happen in a vacuum. Every big company started small, and its important that larger companies encourage startups, and help provide funding through programs such as the Quick Pitch Competitionespecially if theyre in your field. Its good for business and for everyone who lives and works in Americas finest region.

Duane Cameron has more than 30 years of experience in the telecommunications industry. He is vice president for Cox Business, helping to bring innovative products and services to Southern California businesses.

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support was last modified: October 17th, 2019 by Editor

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read the rest here:

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support - Times of San Diego

October 21, 2019

Companion animals affect us in unique ways. They dont judge us. They dont compete with us like other humans. They provide us with emotional support, and in return, we love them dearly.

Reading Time: 4 minutes

Companion animals affect us in unique ways. They dont judge us. They dont compete with us like other humans. They provide us with emotional support, and in return, we love them dearly.

My feline companion of almost twenty years recently died. Silos lived a good, loved life and had a peaceful death at home, with my husband, Patrick, and me there with him. Nevertheless, for some time after Silos death, I felt utterly destroyed. Even though I have many times mourned the death of close grandparents, cousins, and friends, after Siloss death, I sank into depths of despair I have never felt before in my life.

Should I be ashamed to admit this? Should I be embarrassed? Our society would have me think that I should not grieve the death of an animal more than that of a human. Indeed, in my conversations with many patients and non-patients who lost companion animals, I have found that most people have felt pressured to downplay their love for those animals. Although this is gradually changing, too often, instead of giving compassion and empathy, colleagues, friends, and even family members tell those who mourn an animal that they are being silly to care so much after all, they are just animals. Get over it, they say. Buck up!

We laugh together and cry alone. Grief is even lonelier when an animal dies because its less valued than grief over the death of another human. Sociologists, psychologists, and psychiatrists have been slow to appreciate the impact of the loss of an animal. But studies show that an animals death can cause poor sleep, missed days from work, significant distress, and depression. Among those who lose animals they deeply love, the extent of their grief is similar to that of those mourning the death of a cherished person.

It should not come as a surprise that humans are capable of deep affection and love for other animals, be they dogs, cats, or rescued pigs, raccoons, chickens or horses. In the early 1980s, biologist Edward O. Wilson recognized and defined the human innate desire to connect with other living beings as biophilia. It is the hypothesis that humans naturally connect with nature and animals and that our affinity is rooted in our biology. It is a love of life in its simplest definition. It is part of who we are as fellow animals on this planet. Wilson wasnt necessarily arguing that we all seek a bond with animals, but I believe that it is in our relationships with animals where our biophilia is especially evident.

Almost two-thirds of American households include animals as part of their families. And when we cant bring animals into our homes, we look for them elsewhere. We visit wildlife sanctuaries, we join bird watching clubs, we take safaris in Africa, and we watch countless YouTube videos of animals doing things and behaving in ways we thought only humans do. We seek a bond with animals. Our need to be with animals is so deep and instinctively strong that our biology is not just biophilia. It is animalphilia.

We choose to connect with animals. When we encounter another animal, no matter how fleeting that moment may be, we know that we are not alone. And that is comforting.

In fact, how we experience empathy toward animals may not be so different from how we experience it toward other humans. Researchers from the Department of Psychology at Brandeis University and the Pennsylvania State University found that when we are shown pictures of either humans suffering or dogs suffering, there is a great deal of overlap in our neural responses to both.

When we empathize with and connect with animals, we expand our social circle beyond our species. This expansion can lead to remarkable, and often startling, benefits. Studies are showing that animal companionship can reduce our risk of heart disease, increase longevity, lower our cholesterol levels, boost our mental health, and reduce stress. When you walk through your front door at the end of a stressful day and your critter greets you, cant you just feel your blood pressure lowering? Stroking an animal relaxes our autonomic systems, as measured by blood pressure, cortisol, and epinephrine levels, and by respiratory rates and skin temperature.

And heres an important thing to note: Other species arent just substitutes for humans. The social support animals provide is independent of human social support. Animals seem to affect us in unique ways. They dont judge us (except by how kind we are to them). They dont compete with us like other humans and they offer us emotional and psychological release. As a result, animals defuse a lot of the human-generated pressure in our lives. Animals remind us that the world is larger than us. They can teach us to look beyond the racism, poverty, and cruelty in our lives to step out of our daily struggles and see the beauty that surrounds us.

Perhaps its now time to acknowledge freely and openly that loving another animal is a unique and wonderful experience that should never be dismissed as insignificant. The animals in our lives are not mere shadows of human companionship. Animals are individuals in their own right; unique beings who enrich our lives with their friendships. Rather than discounting the innate human bond with other species, we should embrace it for the wonderful gift it is.

Silos gifted Patrick and me daily. He helped us experience the pure joys of just being silly, of feeling unconditional love, and of being completely in the moment. I miss his chasing the laser light around the house. I miss his nightly operas. I miss his drooling when he is kneading my stomach. I miss his yelling at me to get up when I sleep in on weekends. I miss his warm body next to mine when we sleep. I miss him. I miss Silos so deeply; it hurts. And I say this without any shame.

I dont miss my pet. I dont miss my cat. I miss my Silos.

Originally posted here:

To Love and Mourn an Animal - Sentient Media